{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:32:38Z","timestamp":1789475558927,"version":"build-2803163510"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,16]]},"DOI":"10.7759\/cureus.105307","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:54:26Z","timestamp":1773665666000},"source":"Crossref","is-referenced-by-count":1,"title":["Incidence and Comparative Risk of Hematological Adverse Events Across Different Immune Checkpoint Inhibitors: A Network Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.7759","author":[{"given":"Jaahnavi","family":"Vajje","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nafisa","family":"Reyaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Gillani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Muneeb Ullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandipkumar S","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidra","family":"Jabeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin R","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray F","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024, 74:229-63. 10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas A","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018, 359:1350-5. 10.1126\/science.aar4060","journal-title":"Science"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll DM","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012, 12:252-64. 10.1038\/nrc3239","journal-title":"Nat Rev Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow MA","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018, 378:158-68. 10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study","volume":"6","author":"Delanoy N","year":"2019","unstructured":"Delanoy N, Michot JM, Comont T, et al.. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol. 2019, 6:48-57. 10.1016\/S2352-3026(18)30175-3","journal-title":"Lancet Haematol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25448","article-title":"Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors","volume":"94","author":"Leaf RK","year":"2019","unstructured":"Leaf RK, Ferreri C, Rangachari D, et al.. Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. Am J Hematol. 2019, 94:563-74. 10.1002\/ajh.25448","journal-title":"Am J Hematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-59710-3","article-title":"Factors associated with hematological adverse reactions of drugs authorized via the centralized procedure","volume":"14","author":"Stevi\u0107 I","year":"2024","unstructured":"Stevi\u0107 I, Jankovi\u0107 SM, Georgiev AM, Marinkovi\u0107 V, Laki\u0107 D. Factors associated with hematological adverse reactions of drugs authorized via the centralized procedure. Sci Rep. 2024, 14:9074. 10.1038\/s41598-024-59710-3","journal-title":"Sci Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.07.129","article-title":"Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis","volume":"103","author":"Petrelli F","year":"2018","unstructured":"Petrelli F, Ardito R, Borgonovo K, Lonati V, Cabiddu M, Ghilardi M, Barni S. Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. Eur J Cancer. 2018, 103:7-16. 10.1016\/j.ejca.2018.07.129","journal-title":"Eur J Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang DY","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, et al.. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018, 4:1721-8. 10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE- 006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert C","year":"2019","unstructured":"Robert C, Ribas A, Schachter J, et al.. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE- 006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019, 20:1239-51. 10.1016\/S1470-2045(19)30388-2","journal-title":"Lancet Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong J","year":"2018","unstructured":"Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018, 6:8. 10.1186\/s40425-018-0316-z","journal-title":"J Immunother Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally RK","year":"2020","unstructured":"Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel). 2020, 12:10.3390\/cancers12030738","journal-title":"Cancers (Basel)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-016-1583-7","article-title":"Network meta-analysis: an introduction for clinicians","volume":"12","author":"Rouse B","year":"2017","unstructured":"Rouse B, Chaimani A, Li T. Network meta-analysis: an introduction for clinicians. Intern Emerg Med. 2017, 12:103-11. 10.1007\/s11739-016-1583-7","journal-title":"Intern Emerg Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti G","year":"2011","unstructured":"Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011, 64:163-71. 10.1016\/j.jclinepi.2010.03.016","journal-title":"J Clin Epidemiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton B","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, et al.. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015, 162:777-84. 10.7326\/M14-2385","journal-title":"Ann Intern Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2016.02.025","article-title":"[The PRISMA statement extension for systematic reviews incorporating network meta-analysis: PRISMA-NMA]","volume":"147","author":"Hutton B","year":"2016","unstructured":"Hutton B, Catal\u00e1-L\u00f3pez F, Moher D. [The PRISMA statement extension for systematic reviews incorporating network meta-analysis: PRISMA-NMA]. Med Clin (Barc). 2016, 147:262-6. 10.1016\/j.medcli.2016.02.025","journal-title":"Med Clin (Barc)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.2165","article-title":"The Cochrane risk of bias assessment tool 2 (RoB 2) versus the original RoB: a perspective on the pros and cons","volume":"7","author":"Nejadghaderi SA","year":"2024","unstructured":"Nejadghaderi SA, Balibegloo M, Rezaei N. The Cochrane risk of bias assessment tool 2 (RoB 2) versus the original RoB: a perspective on the pros and cons. Health Sci Rep. 2024, 7:e2165. 10.1002\/hsr2.2165","journal-title":"Health Sci Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes J","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS, et al.. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020, 396:1817-28. 10.1016\/S0140-6736(20)32531-9","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki Y","year":"2022","unstructured":"Doki Y, Ajani JA, Kato K, et al.. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022, 386:449-62. 10.1056\/NEJMoa2111380","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo controlled phase 3 trial","volume":"395","author":"Galsky MD","year":"2020","unstructured":"Galsky MD, Arija JAA, Bamias A, et al.. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo controlled phase 3 trial. Lancet. 2020, 395:1547-57. 10.1016\/S0140-6736(20)30230-0","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi L","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, et al.. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018, 378:2078-92. 10.1056\/NEJMoa1801005","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.7629","article-title":"Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer","volume":"35","author":"Govindan R","year":"2017","unstructured":"Govindan R, Szczesna A, Ahn MJ, et al.. Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer. J Clin Oncol. 2017, 35:3449-57. 10.1200\/JCO.2016.71.7629","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemu rafenib, and cobimetinib as first-line treatment for unre sectable advanced BRAF(V600) mutation-positive mela noma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer R","year":"2020","unstructured":"Gutzmer R, Stroyakovskiy D, Gogas H, et al.. Atezolizumab, vemu rafenib, and cobimetinib as first-line treatment for unre sectable advanced BRAF(V600) mutation-positive mela noma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020, 395:1835-44. 10.1016\/S0140-6736(20)30934-X","journal-title":"Lancet"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi FS","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF, et al.. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010, 363:711-23. 10.1056\/NEJMoa1003466","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn L","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A, et al.. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018, 379:2220-9. 10.1056\/NEJMoa1809064","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian YY","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al.. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021, 398:27-40. 10.1016\/S0140-6736(21)00797-2","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.03.028","article-title":"Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (Impower131): results from a randomized phase\u00a0III trial","volume":"15","author":"Jotte R","year":"2020","unstructured":"Jotte R, Cappuzzo F, Vynnychenko I, et al.. Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (Impower131): results from a randomized phase\u00a0III trial. J Thorac Oncol. 2020, 15:1351-60. 10.1016\/j.jtho.2020.03.028","journal-title":"J Thorac Oncol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with her2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal","volume":"23","author":"Kang Y-K","year":"2022","unstructured":"Kang Y-K, Chen L-T, Ryu M-H, et al.. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with her2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal. Lancet Oncol. 2022, 23:234-47. 10.1016\/S1470-2045(21)00692-6","journal-title":"Lancet Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE- 966): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"401","author":"Kelley RK","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, et al.. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE- 966): a randomised, double-blind, placebo-controlled, phase 3 trial.. Lancet. 2023, 401:1853-65. 10.1016\/S0140-6736(23)00727-4","journal-title":"Lancet"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon ED","year":"2014","unstructured":"Kwon ED, Drake CG, Scher HI, et al.. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014, 15:700-12. 10.1016\/S1470-2045(14)70189-5","journal-title":"Lancet Oncol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus standard of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double blind, placebo-controlled, multicentre phase 3 trial","volume":"22","author":"Lee NY","year":"2021","unstructured":"Lee NY, Ferris RL, Psyrri A, et al.. Avelumab plus standard of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double blind, placebo-controlled, multicentre phase 3 trial. Lancet Oncol. 2021, 22:450-62. 10.1016\/S1470-2045(20)30737-3","journal-title":"Lancet Oncol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068714","article-title":"Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial","volume":"377","author":"Lu Z","year":"2022","unstructured":"Lu Z, Wang J, Shu Y, et al.. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ. 2022, 377:e068714. 10.1136\/bmj-2021-068714","journal-title":"BMJ"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial","volume":"326","author":"Luo H","year":"2021","unstructured":"Luo H, Lu J, Bai Y, et al.. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA. 2021, 326:916-25. 10.1001\/jama.2021.12836","journal-title":"JAMA"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with re lapsed or refractory multiple myeloma (KEYNOTE- 183): a randomised, open-label, phase 3 trial","volume":"6","author":"Mateos MV","year":"2019","unstructured":"Mateos MV, Blacklock H, Schjesvold F, et al.. Pembrolizumab plus pomalidomide and dexamethasone for patients with re lapsed or refractory multiple myeloma (KEYNOTE- 183): a randomised, open-label, phase 3 trial. Lancet Haematol. 2019, 6:459-69. 10.1016\/S2352-3026(19)30110-3","journal-title":"Lancet Haematol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles D","year":"2021","unstructured":"Miles D, Gligorov J, Andr\u00e9 F, et al.. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer. Ann Oncol. 2021, 32:994-1004. 10.1016\/j.annonc.2021.05.801","journal-title":"Ann Oncol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthra cycline-based chemotherapy versus placebo and chemo therapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf EA","year":"2020","unstructured":"Mittendorf EA, Zhang H, Barrios CH, et al.. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthra cycline-based chemotherapy versus placebo and chemo therapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020, 396:1090-100. 10.1016\/S0140-6736(20)31953-X","journal-title":"Lancet"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, bevacizum ab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39)","volume":"39","author":"Moore KN","year":"2021","unstructured":"Moore KN, Bookman M, Sehouli J, et al.. Atezolizumab, bevacizum ab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39). J Clin Oncol. 2021, 39:1842-55. 10.1200\/JCO.21.00306","journal-title":"J Clin Oncol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.11.025","article-title":"Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial","volume":"16","author":"Nishio M","year":"2021","unstructured":"Nishio M, Barlesi F, West H, et al.. Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial. J Thorac Oncol. 2021, 16:653-64. 10.1016\/j.jtho.2020.11.025","journal-title":"J Thorac Oncol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles T","year":"2020","unstructured":"Powles T, Park SH, Voog E, et al.. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020, 383:1218-30. 10.1056\/NEJMoa2002788","journal-title":"N Engl J Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or com bined with chemotherapy versus chemotherapy as first line therapy for advanced urothelial carcinoma (KEY NOTE- 361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles T","year":"2021","unstructured":"Powles T, Csoszi T, Ozguroglu M, et al.. Pembrolizumab alone or com bined with chemotherapy versus chemotherapy as first line therapy for advanced urothelial carcinoma (KEY NOTE- 361): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021, 22:931-45. 10.1016\/S1470-2045(21)00152-2","journal-title":"Lancet Oncol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine E","year":"2021","unstructured":"Pujade-Lauraine E, Fujiwara K, Ledermann JA, et al.. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncol. 2021, 22:1034-46. 10.1016\/S1470-2045(21)00216-3","journal-title":"Lancet Oncol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.6601","article-title":"Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer","volume":"34","author":"Reck M","year":"2016","unstructured":"Reck M, Luft A, Szczesna A, et al.. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol. 2016, 34:3740-8. 10.1200\/JCO.2016.67.6601","journal-title":"J Clin Oncol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for Her2-negative advanced gastric cancer (Keynote- 859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha SY","year":"2023","unstructured":"Rha SY, Oh D-Y, Ya\u00f1ez P, et al.. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for Her2-negative advanced gastric cancer (Keynote- 859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023, 24:1181-95. 10.1016\/S1470-2045(23)00515-6","journal-title":"Lancet Oncol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or pla cebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, dou ble-blind, phase III KEYNOTE-604 study","volume":"38","author":"Rudin CM","year":"2020","unstructured":"Rudin CM, Awad MM, Navarro A, et al.. Pembrolizumab or pla cebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, dou ble-blind, phase III KEYNOTE-604 study. J Clin Oncol. 2020, 38:2369-79. 10.1200\/JCO.20.00793","journal-title":"J Clin Oncol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid P","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, et al.. Atezolizumab and nab paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018, 379:2108-21. 10.1056\/NEJMoa1809615","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid P","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, et al.. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020, 382:810-21. 10.1056\/NEJMoa1910549","journal-title":"N Engl J Med"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembroli zumab or pembrolizumab plus chemotherapy vs chemo therapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara K","year":"2020","unstructured":"Shitara K, Van Cutsem E, Bang YJ, et al.. Efficacy and safety of pembroli zumab or pembrolizumab plus chemotherapy vs chemo therapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 2020, 6:1571-80. 10.1001\/jamaoncol.2020.3370","journal-title":"JAMA Oncol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski MA","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, et al.. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018, 378:2288-301. 10.1056\/NEJMoa1716948","journal-title":"N Engl J Med"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02179-2","article-title":"First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial","volume":"29","author":"Song Y","year":"2023","unstructured":"Song Y, Zhang B, Xin D, et al.. First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial. Nat Med. 2023, 29:473-82. 10.1038\/s41591-022-02179-2","journal-title":"Nat Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.06.004","article-title":"Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer","volume":"32","author":"Sugawara S","year":"2021","unstructured":"Sugawara S, Lee JS, Kang JH, et al.. Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer. Ann Oncol. 2021, 32:1137-47. 10.1016\/j.annonc.2021.06.004","journal-title":"Ann Oncol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus le nalidomide and dexamethasone for patients with treat ment-naive multiple myeloma (KEYNOTE- 185): a ran domised, open-label, phase 3 trial","volume":"6","author":"Usmani SZ","year":"2019","unstructured":"Usmani SZ, Schjesvold F, Oriol A, et al.. Pembrolizumab plus le nalidomide and dexamethasone for patients with treat ment-naive multiple myeloma (KEYNOTE- 185): a ran domised, open-label, phase 3 trial. Lancet Haematol. 2019, 6:448-58. 10.1016\/S2352-3026(19)30109-7","journal-title":"Lancet Haematol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.02.007","article-title":"Toripalimab plus chemotherapy in treatment-na\u00efve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial","volume":"40","author":"Wang ZX","year":"2022","unstructured":"Wang ZX, Cui C, Yao J, et al.. Toripalimab plus chemotherapy in treatment-na\u00efve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell. 2022, 40:277-288.e3. 10.1016\/j.ccell.2022.02.007","journal-title":"Cancer Cell"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combina tion with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment 74 for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West H","year":"2019","unstructured":"West H, McCleod M, Hussein M, et al.. Atezolizumab in combina tion with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment 74 for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019, 20:924-37. 10.1016\/S1470-2045(19)30167-6","journal-title":"Lancet Oncol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the orient-16 randomized clinical trial","volume":"330","author":"Xu J","year":"2023","unstructured":"Xu J, Jiang H, Pan Y, et al.. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the orient-16 randomized clinical trial. JAMA. 2023, 330:2064-74. 10.1001\/jama.2023.19918","journal-title":"JAMA"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225804","article-title":"Autoimmune hemolytic anemia in chronic lymphocytic leukemia: a comprehensive review","volume":"13","author":"Autore F","year":"2021","unstructured":"Autore F, Pasquale R, Innocenti I, Fresa A, Sora' F, Laurenti L. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: a comprehensive review. Cancers (Basel). 2021, 13:10.3390\/cancers13225804","journal-title":"Cancers (Basel)"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009016","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"139","author":"Kroll MH","year":"2022","unstructured":"Kroll MH, Rojas-Hernandez C, Yee C. Hematologic complications of immune checkpoint inhibitors. Blood. 2022, 139:3594-604. 10.1182\/blood.2020009016","journal-title":"Blood"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27303-7","article-title":"Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer","volume":"12","author":"Hinterleitner C","year":"2021","unstructured":"Hinterleitner C, Str\u00e4hle J, Malenke E, et al.. Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. Nat Commun. 2021, 12:7005. 10.1038\/s41467-021-27303-7","journal-title":"Nat Commun"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.14740\/jh1090","article-title":"Incidence and risk of hematological adverse events associated with immune checkpoint inhibitors: a systematic literature review and meta-analysis","volume":"12","author":"Ohashi T","year":"2023","unstructured":"Ohashi T, Takase-Minegishi K, Maeda A, et al.. Incidence and risk of hematological adverse events associated with immune checkpoint inhibitors: a systematic literature review and meta-analysis. J Hematol. 2023, 12:66-74. 10.14740\/jh1090","journal-title":"J Hematol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03068-2","article-title":"Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival","volume":"71","author":"Haddad TC","year":"2022","unstructured":"Haddad TC, Zhao S, Li M, et al.. Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival. Cancer Immunol Immunother. 2022, 71:1157-65. 10.1007\/s00262-021-03068-2","journal-title":"Cancer Immunol Immunother"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.01.013","article-title":"Hematological immune related adverse events after treatment with immune checkpoint inhibitors","volume":"147","author":"Kramer R","year":"2021","unstructured":"Kramer R, Zaremba A, Moreira A, et al.. Hematological immune related adverse events after treatment with immune checkpoint inhibitors. Eur J Cancer. 2021, 147:170-81. 10.1016\/j.ejca.2021.01.013","journal-title":"Eur J Cancer"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12102559","article-title":"A diagnostic of acquired hemophilia following PD1\/PDL1 inhibitors in advanced melanoma: the experience of two patients and a literature review","volume":"12","author":"Gidaro A","year":"2022","unstructured":"Gidaro A, Palmieri G, Donadoni M, et al.. A diagnostic of acquired hemophilia following PD1\/PDL1 inhibitors in advanced melanoma: the experience of two patients and a literature review. Diagnostics (Basel). 2022, 12:10.3390\/diagnostics12102559","journal-title":"Diagnostics (Basel)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/466726-incidence-and-comparative-risk-of-hematological-adverse-events-across-different-immune-checkpoint-inhibitors-a-network-meta-analysis-of-randomized-controlled-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:54:27Z","timestamp":1773665667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/466726-incidence-and-comparative-risk-of-hematological-adverse-events-across-different-immune-checkpoint-inhibitors-a-network-meta-analysis-of-randomized-controlled-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":61,"URL":"https:\/\/doi.org\/10.7759\/cureus.105307","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,16]]}}}